TEVIMBRA ist in den USA für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom der Speiseröhre in Kombination mit Chemotherapie zugelassen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2025
0mins
Source: Businesswire
FDA Approval of TEVIMBRA: BeiGene, Ltd. announced the FDA's approval of its drug TEVIMBRA® for first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1, based on significant survival improvements shown in clinical trials.
Company Name Change and Commitment: The company plans to change its name to BeOne Medicines Ltd., emphasizing its dedication to developing innovative cancer therapies and improving access to treatments for patients globally.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
